BRCA Share: A Collection of Clinical BRCA Gene Variants

Article Publication

Background
- Hereditary breast cancer accounts for up to 10% of all breast cancer cases, and variants in BRCA1 and BRCA2 may explain 25% to 28% of the familial risk.  
- Assessment of the clinical significance of variants can be challenging, but a resource that contains clinical observations for each variant can facilitate the process. An international partnership of the French Unicancer Genetic Group and Quest Diagnostics was formed to develop such a resource.
- BRCA Share™ is a database to publicly share clinical, genetic, epidemiological, and biological data on BRCA variants, with a primary focus on variants of uncertain significance (VUS). The first commercial participant was Laboratory Corporation of America (LabCorp).

Objective: This publication describes the methods used to create BRCA Share and the resulting contents of the database.

Methods
- The Universal Mutation Databases of the French Unicancer Genetic Group, UMD-BRCA1 and UMD-BRCA2, were augmented with BRCA testing results from Quest Diagnostics and LabCorp.
- The BRCA Share™ databases contain:
  - Patient information (eg, demographic information, disease status of patient and relatives)
  - Sample information (eg, de-identified subject and family identifiers)
  - Mutation information (eg, NGS screening type, variant names, mutation class)
  - Availability of cell line, tumor, or other physical materials
- Investigators compared BRCA Share databases to other collections.

Results
- At the time of the study, over 6,200 unique BRCA variants were contained within the databases, representing an almost 30% increase compared to that previously contained within the UMD-BRCA1/2 databases.
- Of the over 6,200 BRCA variants identified, 334 were newly identified pathogenic or likely pathogenic variants.
  - These new variants increased the total number of pathogenic or likely pathogenic BRCA variants by 20%, to a total of 1,826.
- Of the variants in both BRCA Share and ClinVar, the largest collection of BRCA variants, 74% were classified identically; none of the differences were clinically actionable (ie, a pathogenic variant categorized as benign).
- BRCA Share also allowed users of the database to resolve discordant classifications. For example, there were initially discrepancies in 148 (29%) of submitted classifications, which dropped to 37 (7%) after internal review.

Conclusions
- The public/private partnership that developed the BRCA Share databases demonstrates a data sharing model that provides rapid, free (to academic researchers) access to classification information for genetic variants.

Article published in Human Mutation

Authors

Citation

Webpage

References
Affiliations

1. Aix Marseille Univ, INSERM, GMGF, Marseille, France
2. APHM, Hôpital TIMONE Enfants, Laboratoire de Génétique Moléculaire, Marseille, France
3. Laboratory Corporation of America, Westborough, Massachusetts
4. Quest Diagnostics, Marlborough, Massachusetts
5. Service de Génétique, Département de Biologie des Tumeurs, Institut Curie, Paris, France
6. CHU et Institut Jean Godinot, Reims, France
7. Centre Jean Perrin, Clermont-Ferrand, France
8. Institut Gustave Roussy, Villejuif, France
9. CHU de Nancy-Brabois, Vandoeuvre-lès-Nancy, France
10. Groupe hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Laboratoire d’Oncogénétique et Angiogénétique moléculaire, Université Pierre et Marie Curie, Paris, France
11. CHU, Institut de Biologie, Hôtel Dieu, Nantes, France
12. Université Paris Descartes, Paris, France
13. CHU de Dijon, Hôpital d’Enfants, Service de Génétique Médicale, Dijon, France
14. Centre Paul Strauss, Strasbourg, France
15. Quest Diagnostics, San Juan Capistrano, California
16. Centre Oscar Lambret, Unité d’Oncologie Moléculaire Humaine, Lille, France
17. Institut Bergonié, Bordeaux, France
18. Hospices Civils de Lyon and Centre Léon Bérard, Lyon, France
19. Institut Paoli-Calmettes, Marseille, France
20. Institut Claudius Régaud, Toulouse, France
21. Laboratoire de biologie et de génétique du cancer, CLCC François Baclesse, INSERM 1079 Centre Normand de Génomique et de Médecine Personnalisée, Caen, France
22. Laboratoire de Biologie Cellulaire et Hormonale (CHU Arnaud de Villeneuve), Montpellier, France
23. Laboratory Corporation of America, Research Triangle Park, North Carolina
24. Quest Diagnostics, San Juan Capistrano, California